Stammdaten
Roivant Sciences Ltd., ein biopharmazeutisches und Gesundheitstechnologieunternehmen, erforscht und entwickelt Arzneimittel. Das Unternehmen entwickelt Produktkandidaten für die Behandlung verschiedener therapeutischer Indikationen, einschließlich solider Tumoren, Sichelzellerkrankheiten, Hypophosphatasia, onkologischer Malignome, Psoriasis, atopischer Dermatitis, Vitiligo, Hyperhidrose, Akne, Myasthenia Gravis, warmer autoimmun-hämolytischer Anämie, Schilddrüsenaugenkrankheiten, Sarkoidose und Staphylococcus-aureus-Bakteriämie. Das Unternehmen wurde 2014 gegründet und hat seinen Sitz in London, Vereinigtes Königreich.
Unternehmen & Branche
| Name | Roivant Sciences Ltd. |
|---|---|
| Ticker | ROIV |
| CIK | 0001635088 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | G76279101 |
|---|---|
| ISIN | USG762791014 |
| Typ | Common Stock |
| Marktkapitalisierung | 25,91 Mrd. USD |
| Beta | 1,12 |
Sitz & Kontakt
| Sitz (Inkorporation) | Bermuda |
|---|---|
| Geschäftsadresse | 7TH FLOOR, 50 BROADWAY, SW1H 0DB LONDON |
| Telefon | 441-295-5950 |
| EIN (IRS) | 98-1173944 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.03. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 5,72 vs. 2,07 (2022) ▲ |
|---|---|
| KUV (P/S) | 3.136,93 vs. 62,10 (2022) ▲ |
| FCF-Rendite | -2,9 % vs. -20,2 % (2022) ▲ |
Qualität & Bilanz
| Operative Marge | -6.235,7 % vs. -2.444,8 % (2022) ▼ |
|---|---|
| Nettomarge | -3.629,2 % vs. -1.528,9 % (2022) ▼ |
| ROIC | -6,5 % vs. -43,6 % (2022) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.03.2026, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2022. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2022 | 2023 | 2024 | 2025 | 2026 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 2,07 | 4,85 | 1,42 | 1,50 | 4,41 | |
| KUV (P/S) | 62,10 | 177,92 | 259,91 | 241,70 | 2.415,71 | |
| FCF-Rendite | -20,2 % | -15,3 % | -9,0 % | -12,0 % | -3,8 % | |
| Buyback-Rendite | – | 0,0 % | 0,0 % | 18,4 % | – | |
| Qualität & Bilanz | ||||||
| Operative Marge | -2.444,8 % | -2.875,9 % | 13.746,9 % | -3.453,3 % | -6.235,7 % | |
| Nettomarge | -1.528,9 % | -3.200,2 % | 13.294,2 % | -592,0 % | -3.629,2 % | |
| ROIC | -43,6 % | -62,9 % | 67,4 % | -3,6 % | -6,5 % | |
| Zinsdeckungsgrad | -192,0 | -32,4 | 129,3 | – | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ROIV
Roivant Sciences Ltd.
Effektiv
Schwach
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
56,3
90 neu, 166 erhöht, 2569,2M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 31.09 | +12.3 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 25.21 | +38.5 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 34.04 | EMA50: 31.82 | |
| MACD-Histogramm | Bärisch | 10 % | -0.070 | Bearisch | |
| RSI(14) | Neutral | 10 % | 59.7 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 58.2 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 40.8 | +DI: 25.5 / −DI: 15.0 | |
| Z-Score(60) | Bärisch | 5 % | 1.57 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 92.6 % | Hoch 36.81 / Tief 11.17 | |
| Bollinger(20,2σ) | Neutral | 5 % | 61.8 % | Upper 38.02 / Mid 33.95 / Lower 29.87 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1295 | R²=0.68 / annualisiert +106.4 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | QVT Financial LP | Open Market Sale | -12.380 | 35,28 | -436.766,40 | -5,6% | ||
| 2026-06-30 | MANCHESTER KEITH S | Director | Open Market Sale | -200.000 | 35,45 | -7.090.000,00 | -90,3% | |
| 2026-06-30 | MANCHESTER KEITH S | Director | Open Market Sale | -12.380 | 35,28 | -436.766,40 | -5,6% | |
| 2026-06-30 | Gold Daniel Allen | Director | Open Market Sale | -12.380 | 35,28 | -436.766,40 | -5,6% | |
| 2026-06-30 | Fitzgerald Meghan | Director | Open Market Sale | -10.000 | 34,90 | -349.000,00 | -4,4% | |
| 2026-06-29 | Epperly Melissa B, | Director | Open Market Sale | -15.002 | 34,32 | -514.868,64 | -6,6% | |
| 2026-06-29 | MANCHESTER KEITH S | Director | Open Market Sale | -600.000 | 34,59 | -20.754.000,00 | -264,2% | |
| 2026-06-29 | Epperly Melissa B, | Director | Open Market Sale | -2.748 | 34,71 | -95.383,08 | -1,2% | |
| 2026-06-29 | MANCHESTER KEITH S | Director | Open Market Sale | -200.000 | 34,44 | -6.888.000,00 | -87,7% | |
| 2026-06-29 | Gold Daniel Allen | Director | Open Market Sale | -600.000 | 34,59 | -20.754.000,00 | -264,2% | |
| 2026-06-29 | Gold Daniel Allen | Director | Open Market Sale | -200.000 | 34,44 | -6.888.000,00 | -87,7% | |
| 2026-06-29 | QVT Financial LP | Open Market Sale | -600.000 | 34,59 | -20.754.000,00 | -264,2% | ||
| 2026-06-29 | QVT Financial LP | Open Market Sale | -200.000 | 34,44 | -6.888.000,00 | -87,7% | ||
| 2026-06-26 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -500.000 | 34,08 | -17.040.000,00 | -216,9% | |
| 2026-06-26 | QVT Financial LP | Open Market Sale | -325.000 | 34,07 | -11.072.750,00 | -141,0% | ||
| 2026-06-26 | QVT Financial LP | Open Market Sale | -300.783 | 33,92 | -10.202.559,36 | -129,9% | ||
| 2026-06-26 | MANCHESTER KEITH S | Director | Open Market Sale | -325.000 | 34,07 | -11.072.750,00 | -141,0% | |
| 2026-06-26 | MANCHESTER KEITH S | Director | Open Market Sale | -300.783 | 33,92 | -10.202.559,36 | -129,9% | |
| 2026-06-26 | Gold Daniel Allen | Director | Open Market Sale | -325.000 | 34,07 | -11.072.750,00 | -141,0% | |
| 2026-06-26 | Gold Daniel Allen | Director | Open Market Sale | -300.783 | 33,92 | -10.202.559,36 | -129,9% | |
| 2026-06-25 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -500.000 | 34,13 | -17.065.000,00 | -217,2% | |
| 2026-06-24 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -46.234 | 33,51 | -1.549.301,34 | -19,7% | |
| 2026-06-24 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -153.766 | 33,05 | -5.081.966,30 | -64,7% | |
| 2026-05-22 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 30,27 | -6.054.000,00 | -77,1% | |
| 2026-04-20 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 29,59 | -5.918.000,00 | -75,3% | |
| 2026-04-16 | Gline Matthew | Director, Officer, CEO | Open Market Sale | -289.774 | 29,16 | -8.449.809,84 | -107,6% | |
| 2026-04-08 | Humes Jennifer | Officer, Chief Accounting Officer | Open Market Sale | -13.538 | 28,37 | -384.073,06 | -4,9% | |
| 2026-03-26 | Fitzgerald Meghan | Director | Open Market Sale | -70.000 | 27,45 | -1.921.500,00 | -24,5% | |
| 2026-03-17 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 28,24 | -5.648.000,00 | -71,9% | |
| 2026-03-16 | Epperly Melissa B, | Director | Open Market Sale | -41.861 | 28,68 | -1.200.573,48 | -15,3% | |
| 2026-02-23 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -587.390 | 27,51 | -16.159.098,90 | -205,7% | |
| 2026-02-20 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1.012.610 | 27,15 | -27.492.361,50 | -350,0% | |
| 2026-02-19 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1.400.000 | 27,42 | -38.388.000,00 | -488,7% | |
| 2026-02-13 | MANCHESTER KEITH S | Director | Open Market Sale | -225.000 | 26,50 | -5.962.500,00 | -75,9% | |
| 2026-02-13 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 26,49 | -5.298.000,00 | -67,4% | |
| 2026-02-13 | QVT Financial LP | Open Market Sale | -225.000 | 26,50 | -5.962.500,00 | -75,9% | ||
| 2026-02-13 | QVT Financial LP | Open Market Sale | -150.784 | 26,49 | -3.994.268,16 | -50,8% | ||
| 2026-02-13 | Gold Daniel Allen | Director | Open Market Sale | -225.000 | 26,50 | -5.962.500,00 | -75,9% | |
| 2026-02-13 | Gold Daniel Allen | Director | Open Market Sale | -150.784 | 26,49 | -3.994.268,16 | -50,8% | |
| 2026-02-13 | MANCHESTER KEITH S | Director | Open Market Sale | -150.784 | 26,49 | -3.994.268,16 | -50,8% | |
| 2026-02-12 | Gold Daniel Allen | Director | Open Market Sale | -150.000 | 26,72 | -4.008.000,00 | -51,0% | |
| 2026-02-12 | MANCHESTER KEITH S | Director | Open Market Sale | -275.000 | 26,76 | -7.359.000,00 | -93,7% | |
| 2026-02-12 | Gold Daniel Allen | Director | Open Market Sale | -275.000 | 26,76 | -7.359.000,00 | -93,7% | |
| 2026-02-12 | QVT Financial LP | Open Market Sale | -275.000 | 26,76 | -7.359.000,00 | -93,7% | ||
| 2026-02-12 | QVT Financial LP | Open Market Sale | -150.000 | 26,72 | -4.008.000,00 | -51,0% | ||
| 2026-02-12 | MANCHESTER KEITH S | Director | Open Market Sale | -150.000 | 26,72 | -4.008.000,00 | -51,0% | |
| 2026-02-11 | MANCHESTER KEITH S | Director | Open Market Sale | -425.000 | 26,67 | -11.334.750,00 | -144,3% | |
| 2026-02-11 | QVT Financial LP | Open Market Sale | -425.000 | 26,67 | -11.334.750,00 | -144,3% | ||
| 2026-02-11 | Gold Daniel Allen | Director | Open Market Sale | -425.000 | 26,67 | -11.334.750,00 | -144,3% | |
| 2026-02-09 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -339.441 | 26,47 | -8.985.003,27 | -114,4% | |
| 2026-01-12 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 21,92 | -4.384.000,00 | -55,8% | |
| 2025-12-31 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -1.018.995 | 21,71 | -22.122.381,45 | -281,6% | |
| 2025-12-29 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -311.873 | 21,74 | -6.780.119,02 | -86,3% | |
| 2025-12-24 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -75.000 | 22,53 | -1.689.750,00 | -21,5% | |
| 2025-12-23 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 22,45 | -4.490.000,00 | -57,2% | |
| 2025-12-23 | Pulik Richard | Officer, CFO | Open Market Sale | -146.731 | 22,39 | -3.285.307,09 | -41,8% | |
| 2025-12-23 | Pulik Richard | Officer, CFO | Open Market Sale | -260.000 | 22,45 | -5.837.000,00 | -74,3% | |
| 2025-12-17 | QVT Financial LP | Open Market Sale | -432.718 | 23,05 | -9.974.149,90 | -127,0% | ||
| 2025-12-17 | QVT Financial LP | Open Market Sale | -155.076 | 23,02 | -3.569.849,52 | -45,4% | ||
| 2025-12-17 | Gold Daniel Allen | Director | Open Market Sale | -432.718 | 23,05 | -9.974.149,90 | -127,0% | |
| 2025-12-17 | Gold Daniel Allen | Director | Open Market Sale | -189.538 | 23,17 | -4.391.595,46 | -55,9% | |
| 2025-12-17 | Gold Daniel Allen | Director | Open Market Sale | -155.076 | 23,02 | -3.569.849,52 | -45,4% | |
| 2025-12-17 | QVT Financial LP | Open Market Sale | -189.538 | 23,17 | -4.391.595,46 | -55,9% | ||
| 2025-12-17 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -26.831 | 23,09 | -619.527,79 | -7,9% | |
| 2025-12-17 | MANCHESTER KEITH S | Director | Open Market Sale | -432.718 | 23,05 | -9.974.149,90 | -127,0% | |
| 2025-12-17 | MANCHESTER KEITH S | Director | Open Market Sale | -189.538 | 23,17 | -4.391.595,46 | -55,9% | |
| 2025-12-17 | MANCHESTER KEITH S | Director | Open Market Sale | -155.076 | 23,02 | -3.569.849,52 | -45,4% | |
| 2025-12-16 | Gold Daniel Allen | Director | Open Market Sale | -642.282 | 23,08 | -14.823.868,56 | -188,7% | |
| 2025-12-16 | QVT Financial LP | Open Market Sale | -642.282 | 23,08 | -14.823.868,56 | -188,7% | ||
| 2025-12-16 | QVT Financial LP | Open Market Sale | -275.000 | 22,93 | -6.305.750,00 | -80,3% | ||
| 2025-12-16 | MANCHESTER KEITH S | Director | Open Market Sale | -642.282 | 23,08 | -14.823.868,56 | -188,7% | |
| 2025-12-16 | MANCHESTER KEITH S | Director | Open Market Sale | -275.000 | 22,93 | -6.305.750,00 | -80,3% | |
| 2025-12-16 | Gold Daniel Allen | Director | Open Market Sale | -275.000 | 22,93 | -6.305.750,00 | -80,3% | |
| 2025-12-15 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -353.745 | 22,05 | -7.800.077,25 | -99,3% | |
| 2025-12-15 | Gline Matthew | Director, Officer, CEO | Open Market Sale | -943.527 | 21,68 | -20.455.665,36 | -260,4% | |
| 2025-12-15 | Gline Matthew | Director, Officer, CEO | Open Market Sale | -566.116 | 21,68 | -12.273.394,88 | -156,2% | |
| 2025-12-15 | Gline Matthew | Director, Officer, CEO | Open Market Sale | -230.357 | 21,68 | -4.994.139,76 | -63,6% | |
| 2025-12-12 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1.975.858 | 21,96 | -43.389.841,68 | -552,4% | |
| 2025-12-11 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -774.142 | 21,64 | -16.752.432,88 | -213,3% | |
| 2025-12-09 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 20,85 | -4.170.000,00 | -53,1% | |
| 2025-11-19 | MANCHESTER KEITH S | Director | Open Market Sale | -125.000 | 20,16 | -2.520.000,00 | -32,1% | |
| 2025-11-19 | QVT Financial LP | Open Market Sale | -850.000 | 20,25 | -17.212.500,00 | -219,1% | ||
| 2025-11-19 | QVT Financial LP | Open Market Sale | -175.000 | 20,24 | -3.542.000,00 | -45,1% | ||
| 2025-11-19 | QVT Financial LP | Open Market Sale | -150.000 | 20,20 | -3.030.000,00 | -38,6% | ||
| 2025-11-19 | QVT Financial LP | Open Market Sale | -125.000 | 20,16 | -2.520.000,00 | -32,1% | ||
| 2025-11-19 | Gold Daniel Allen | Director | Open Market Sale | -850.000 | 20,25 | -17.212.500,00 | -219,1% | |
| 2025-11-19 | Gold Daniel Allen | Director | Open Market Sale | -175.000 | 20,24 | -3.542.000,00 | -45,1% | |
| 2025-11-19 | Gold Daniel Allen | Director | Open Market Sale | -150.000 | 20,20 | -3.030.000,00 | -38,6% | |
| 2025-11-19 | Gold Daniel Allen | Director | Open Market Sale | -125.000 | 20,16 | -2.520.000,00 | -32,1% | |
| 2025-11-19 | MANCHESTER KEITH S | Director | Open Market Sale | -850.000 | 20,25 | -17.212.500,00 | -219,1% | |
| 2025-11-19 | MANCHESTER KEITH S | Director | Open Market Sale | -175.000 | 20,24 | -3.542.000,00 | -45,1% | |
| 2025-11-19 | MANCHESTER KEITH S | Director | Open Market Sale | -150.000 | 20,20 | -3.030.000,00 | -38,6% | |
| 2025-11-17 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -539.650 | 20,51 | -11.068.221,50 | -140,9% | |
| 2025-11-14 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1.027.670 | 20,33 | -20.892.531,10 | -266,0% | |
| 2025-11-13 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -287.283 | 20,81 | -5.978.359,23 | -76,1% | |
| 2025-11-07 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200.000 | 20,22 | -4.044.000,00 | -51,5% | |
| 2025-10-17 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -118.418 | 17,06 | -2.020.211,08 | -25,7% | |
| 2025-10-16 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -318.282 | 17,05 | -5.426.708,10 | -69,1% | |
| 2025-10-15 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -414.683 | 16,93 | -7.020.583,19 | -89,4% | |
| 2025-10-13 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -20.727 | 16,25 | -336.813,75 | -4,3% | |
| 2025-10-09 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -104.940 | 16,30 | -1.710.522,00 | -21,8% | |
| 2025-10-08 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -138.602 | 16,20 | -2.245.352,40 | -28,6% | |
| 2025-10-07 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -355.161 | 16,15 | -5.735.850,15 | -73,0% | |
| 2025-10-06 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -171.396 | 16,34 | -2.800.610,64 | -35,7% | |
| 2025-09-23 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -611.000 | 14,83 | -9.061.130,00 | -115,3% | |
| 2025-09-22 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -316.182 | 14,99 | -4.739.568,18 | -60,3% | |
| 2025-09-22 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -100.000 | 15,01 | -1.501.000,00 | -19,1% | |
| 2025-09-19 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -683.818 | 14,95 | -10.223.079,10 | -130,1% | |
| 2025-09-18 | Gline Matthew | Director, Officer, CEO | Open Market Purchase | 3.315 | 15,07 | 49.957,05 | +0,6% | |
| 2025-09-05 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -385.816 | 12,96 | -5.000.175,36 | -63,7% | |
| 2025-09-04 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -194.933 | 12,92 | -2.518.534,36 | -32,1% | |
| 2025-09-03 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1.195.000 | 12,50 | -14.937.500,00 | -190,2% | |
| 2025-08-20 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -100.000 | 11,72 | -1.172.000,00 | -14,9% | |
| 2025-07-21 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -100.000 | 11,52 | -1.152.000,00 | -14,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 77.981.253 | 0 | 77.981.253 | 2.160.080.715 | Neu | +100,0% | |
| MORGAN STANLEY | 51.828.325 | 0 | 51.828.325 | 1.435.644.662 | Neu | +100,0% | |
| BlackRock, Inc. | 44.254.260 | 0 | 44.254.260 | 1.225.842.982 | Neu | +100,0% | |
| QVT Financial LP | 25.161.237 | 0 | 25.161.237 | 696.966.265 | Neu | +100,0% | |
| UBS Group AG | 22.619.472 | 0 | 22.619.472 | 626.559.375 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 20.680.572 | 0 | 20.680.572 | 572.851.844 | Neu | +100,0% | |
| STATE STREET CORP | 16.186.613 | 0 | 16.186.613 | 448.369.180 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 12.794.097 | 0 | 12.794.097 | 354.396.487 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 11.111.591 | 0 | 11.111.591 | 307.791.071 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 8.362.952 | 7.076.488 | 1.286.464 | 295.964.871 | Aufgestockt | +18,2% | |
| GEODE CAPITAL MANAGEMENT, LLC | 10.182.477 | 0 | 10.182.477 | 282.113.040 | Neu | +100,0% | |
| Two Seas Capital LP | 10.060.591 | 0 | 10.060.591 | 278.678.371 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.675.000 | 0 | 9.675.000 | 267.997.500 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 8.285.461 | 0 | 8.285.461 | 229.507.270 | Neu | +100,0% | |
| Patient Square Capital LP | 8.166.047 | 0 | 8.166.047 | 226.199.502 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 7.475.866 | 0 | 7.475.866 | 207.004.200 | Neu | +100,0% | |
| VIKING GLOBAL INVESTORS LP | 6.652.448 | 0 | 6.652.448 | 184.272.810 | Neu | +100,0% | |
| Darwin Global Management, Ltd. | 6.797.300 | 0 | 6.797.300 | 179.516.693 | Neu | +100,0% | |
| NATIONAL BANK OF CANADA /FI/ | 6.298.000 | 0 | 6.298.000 | 174.454.600 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 5.946.858 | 0 | 5.946.858 | 161.635.601 | Neu | +100,0% | |
| Rubric Capital Management LP | 5.000.000 | 0 | 5.000.000 | 138.500.000 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 4.867.723 | 0 | 4.867.723 | 134.835.927 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 3.520.452 | 0 | 3.520.452 | 97.516.520 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.457.448 | 0 | 3.457.448 | 95.771.310 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 3.450.904 | 0 | 3.450.904 | 95.590.041 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 3.285.906 | 0 | 3.285.906 | 91.019.596 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 3.163.821 | 0 | 3.163.821 | 87.637.843 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 3.095.448 | 0 | 3.095.448 | 85.790.341 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 2.982.799 | 0 | 2.982.799 | 82.623.519 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 2.800.000 | 0 | 2.800.000 | 77.560.000 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 2.723.198 | 0 | 2.723.198 | 75.432.585 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 2.673.233 | 0 | 2.673.233 | 74.048.554 | Neu | +100,0% | |
| SB INVESTMENT ADVISERS (UK) LTD | 2.671.732 | 0 | 2.671.732 | 74.006.976 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 2.516.353 | 0 | 2.516.353 | 69.702.978 | Neu | +100,0% | |
| BlackBarn Capital Partners LP | 2.285.117 | 0 | 2.285.117 | 63.297.741 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 2.246.943 | 0 | 2.246.943 | 62.240.321 | Neu | +100,0% | |
| DME Capital Management, LP | 2.152.669 | 0 | 2.152.669 | 59.628.931 | Neu | +100,0% | |
| PENN DAVIS MCFARLAND INC | 1.580.191 | 1.592.623 | -12.432 | 55.922.959 | Reduziert | -0,8% | |
| Clearbridge Investments, LLC | 2.005.565 | 0 | 2.005.565 | 55.554.150 | Neu | +100,0% | |
| Candriam S.C.A. | 2.001.976 | 0 | 2.001.976 | 55.454.735 | Neu | +100,0% | |
| Integral Health Asset Management, LLC | 2.000.000 | 0 | 2.000.000 | 55.400.000 | Neu | +100,0% | |
| Nuveen, LLC | 1.955.046 | 0 | 1.955.046 | 54.154.775 | Neu | +100,0% | |
| Woodline Partners LP | 1.750.017 | 0 | 1.750.017 | 48.475.471 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.741.480 | 0 | 1.741.480 | 48.238.995 | Neu | +100,0% | |
| MAVERICK CAPITAL LTD | 1.626.940 | 0 | 1.626.940 | 45.066.238 | Neu | +100,0% | |
| CITIGROUP INC | 1.590.110 | 0 | 1.590.110 | 44.046.047 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 1.578.308 | 0 | 1.578.308 | 43.719.132 | Neu | +100,0% | |
| Amundi | 1.480.970 | 0 | 1.480.970 | 41.022.869 | Neu | +100,0% | |
| Whitefort Capital Management, LP | 1.419.000 | 0 | 1.419.000 | 39.306.300 | Neu | +100,0% | |
| Gotham Asset Management, LLC | 1.416.091 | 0 | 1.416.091 | 39.225.721 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 8.362.952 | 7.076.488 | +18,2% | 295.964.871 | 75,94 | 100 % | 9 Q |
| PENN DAVIS MCFARLAND INC | 1.580.191 | 1.592.623 | -0,8% | 55.922.959 | 14,35 | 100 % | 10 Q |
| Cache Advisors, LLC | 538.600 | 0 | +100,0% | 19.061.054 | 4,89 | 100 % | 1 Q |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC | 197.419 | 0 | +100,0% | 6.986.632 | 1,79 | 0 % | 1 Q |
| Y-Intercept (Hong Kong) Ltd | 110.340 | 0 | +100,0% | 3.904.933 | 1,00 | 100 % | 6 Q |
| Edge Wealth Management LLC | 90.228 | 90.228 | 0,0% | 3.193.169 | 0,82 | 100 % | 16 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 40.367 | 35.849 | +12,6% | 1.452.014 | 0,37 | 3 % | 3 Q |
| Ledgewood Wealth Advisors, LLC | 32.970 | 32.970 | 0,0% | 1.166.808 | 0,30 | 0 % | 11 Q |
| Wedmont Private Capital | 15.587 | 15.817 | -1,5% | 560.664 | 0,14 | 0 % | 6 Q |
| GAMMA Investing LLC | 14.637 | 12.465 | +17,4% | 518.003 | 0,13 | 100 % | 11 Q |
| DAVENPORT & Co LLC | 13.600 | 10.600 | +28,3% | 481.304 | 0,12 | 100 % | 13 Q |
| Douglas Lane & Associates, LLC | 7.886 | 7.886 | 0,0% | 279.086 | 0,07 | 0 % | 2 Q |
| Versant Capital Management, Inc | 3.995 | 3.508 | +13,9% | 141.383 | 0,04 | 100 % | 8 Q |
| MassMutual Private Wealth & Trust, FSB | 1.066 | 904 | +17,9% | 37.726 | 0,01 | 100 % | 7 Q |
| THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 455 | 455 | 0,0% | 16.102 | 0,00 | 100 % | 6 Q |
| Marquette Asset Management, LLC | 267 | 284 | -6,0% | 9.450 | 0,00 | 0 % | 4 Q |
| JFS WEALTH ADVISORS, LLC | 247 | 204 | +21,1% | 8.742 | 0,00 | 0 % | 4 Q |
| Handelsbanken Fonder AB | 177.209 | 117.009 | +51,4% | 6.271 | 0,00 | 0 % | 15 Q |
| Sachetta, LLC | 143 | 124 | +15,3% | 5.061 | 0,00 | 0 % | 7 Q |
| Aventura Private Wealth, LLC | 124 | 124 | 0,0% | 4.388 | 0,00 | 100 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 29 | 11,2 | 390 |
| 31.03.2026 | ✓ | 435 | 562,3 | 15.286 |
| 31.12.2025 | ✓ | 390 | 581,9 | 17.328 |
| 30.09.2025 | ✓ | 333 | 546,9 | 10.230 |
| 30.06.2025 | ✓ | 334 | 582,7 | 6.466 |
| 31.03.2025 | ✓ | 309 | 564,6 | 5.624 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 20.680.572 | 572.851.844 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.675.000 | 267.997.500 |
| Darwin Global Management, Ltd. | 6.797.300 | 179.516.693 |
| MAVERICK CAPITAL LTD | 1.626.940 | 45.066.238 |
| WELLINGTON MANAGEMENT GROUP LLP | 963.282 | 26.682.911 |
| Point72 Asset Management, L.P. | 890.900 | 24.677.930 |
| Cormorant Asset Management, LP | 750.000 | 20.775.000 |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 691.463 | 19.153.525 |
| Cinctive Capital Management LP | 274.521 | 7.604.232 |
| XTX Topco Ltd | 255.431 | 7.075.439 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 77.981.253 | 12.201.789 | +18.5 % | 2.160.080.715 |
| AQR CAPITAL MANAGEMENT LLC | 5.946.858 | 5.066.085 | +575.2 % | 161.635.601 |
| NATIONAL BANK OF CANADA /FI/ | 6.298.000 | 4.258.000 | +208.7 % | 174.454.600 |
| UBS Group AG | 22.619.472 | 4.228.680 | +23.0 % | 626.559.375 |
| BlackRock, Inc. | 44.254.260 | 3.083.785 | +7.5 % | 1.225.842.982 |
| Qube Research & Technologies Ltd | 3.450.904 | 2.691.685 | +354.5 % | 95.590.041 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 12.794.097 | 2.116.203 | +19.8 % | 354.396.487 |
| GEODE CAPITAL MANAGEMENT, LLC | 10.182.477 | 2.028.931 | +24.9 % | 282.113.040 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.992.136 | 1.657.011 | +31.1 % | 193.683 |
| Integral Health Asset Management, LLC | 2.000.000 | 1.150.000 | +135.3 % | 55.400.000 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 2.671.732 | -13.741.871 | -83.7 % | 74.006.976 |
| MORGAN STANLEY | 51.828.325 | -6.531.228 | -11.2 % | 1.435.644.662 |
| Rubric Capital Management LP | 5.000.000 | -4.000.000 | -44.4 % | 138.500.000 |
| Jefferies Financial Group Inc. | 7.266 | -3.507.567 | -99.8 % | 201.268 |
| DIMENSIONAL FUND ADVISORS LP | 7.475.866 | -1.771.602 | -19.2 % | 207.004.200 |
| QVT Financial LP | 25.161.237 | -1.225.784 | -4.6 % | 696.966.265 |
| MARSHALL WACE, LLP | 2.246.943 | -1.211.983 | -35.0 % | 62.240.321 |
| STATE STREET CORP | 16.186.613 | -1.174.852 | -6.8 % | 448.369.180 |
| Polar Capital Holdings Plc | 1.578.308 | -1.111.816 | -41.3 % | 43.719.132 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 196.195 | -1.090.002 | -84.7 % | 5.434.602 |
Zusätzlich aktuell von 57 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 12.05.2026 | Morgan Stanley | Passiv (13G/A) | 6,90 % | 49.473.835 | -1,10 pp | |
| 12.05.2026 | Morgan Stanley Investment Management Inc. | Passiv (13G/A) | 6,70 % | 48.260.685 | -1,10 pp | |
| 06.05.2026 | Ramaswamy Vivek | Passiv (13G/A) | 3,60 % | 25.534.970 | -3,20 pp | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,63 pp | |
| 06.03.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 10,30 % | 73.641.253 | +0,80 pp | |
| 17.02.2026 | SB Investment Advisers (UK) Limited (+3) | Passiv (13G/A) | 2,30 % | 16.413.603 | -3,50 pp | |
| 13.02.2026 | Ramaswamy Vivek | Passiv (13G/A) | 6,80 % | 48.428.792 | -4,83 pp | |
| 11.02.2026 | Morgan Stanley Investment Management Inc. | Passiv (13G/A) | 7,80 % | 54.403.260 | +2,40 pp | |
| 11.02.2026 | Morgan Stanley | Passiv (13G/A) | 8,00 % | 55.491.570 | +2,50 pp | |
| 05.02.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 9,50 % | 65.779.464 | +1,30 pp | |
| 14.11.2025 | SB Investment Advisers (UK) Limited (+3) | Passiv (13G/A) | 5,80 % | 40.315.127 | -2,70 pp | |
| 14.11.2025 | Viking Global Equities II LP | Passiv (13G/A) | 0,04 % | 250.088 | -0,06 pp | |
| 14.11.2025 | VIKING GLOBAL PERFORMANCE LLC | Passiv (13G/A) | 1,80 % | 12.504.401 | -0,90 pp | |
| 14.11.2025 | Viking Global Equities Master Ltd. | Passiv (13G/A) | 1,80 % | 12.254.313 | -0,80 pp | |
| 14.11.2025 | Viking Long Fund Master Ltd. (+1) | Passiv (13G/A) | 0,70 % | 4.851.726 | -0,20 pp | |
| 14.11.2025 | VIKING GLOBAL INVESTORS LP (+3) | Passiv (13G/A) | 3,40 % | 23.594.831 | -1,62 pp | |
| 14.11.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+3) | Passiv (13G/A) | 0,90 % | 6.238.704 | -0,50 pp | |
| 14.08.2025 | QVT Financial LP | Passiv (13G/A) | 4,30 % | 29.381.635 | -4,92 pp | |
| 14.08.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+3) | Passiv (13G/A) | 1,40 % | 9.506.204 | -0,40 pp | |
| 14.08.2025 | Viking Global Equities Master Ltd. | Passiv (13G/A) | 2,60 % | 17.979.927 | -0,80 pp | |
| 14.08.2025 | Viking Long Fund Master Ltd. (+1) | Passiv (13G/A) | 0,90 % | 6.384.710 | -0,40 pp | |
| 14.08.2025 | VIKING GLOBAL INVESTORS LP (+3) | Passiv (13G/A) | 5,02 % | 34.237.779 | -1,38 pp | |
| 14.08.2025 | VIKING GLOBAL PERFORMANCE LLC | Passiv (13G/A) | 2,70 % | 18.346.865 | -0,70 pp | |
| 14.08.2025 | Viking Global Equities II LP | Passiv (13G/A) | 0,10 % | 366.938 | 0,00 pp | |
| 07.08.2025 | Morgan Stanley | Passiv (13G) | 5,50 % | 37.646.676 | Neu | |
| 07.08.2025 | Morgan Stanley Investment Management Inc. | Passiv (13G) | 5,40 % | 36.472.782 | Neu | |
| 06.08.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 8,20 % | 55.509.281 | Neu | |
| 15.05.2025 | Ramaswamy Vivek | Passiv (13G/A) | 11,63 % | 82.956.522 | +0,43 pp | |
| 15.05.2025 | Ramaswamy Vivek | Passiv (13G/A) | 11,20 % | 82.956.521 | Neu | |
| 15.05.2025 | VIKING GLOBAL PERFORMANCE LLC | Passiv (13G/A) | 3,40 % | 24.547.654 | Neu | |
| 15.05.2025 | Viking Global Equities Master Ltd. | Passiv (13G/A) | 3,40 % | 24.056.700 | -0,10 pp | |
| 15.05.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+3) | Passiv (13G/A) | 1,80 % | 12.506.204 | -0,80 pp | |
| 15.05.2025 | Viking Global Equities II LP | Passiv (13G/A) | 0,10 % | 490.954 | 0,00 pp | |
| 15.05.2025 | Viking Long Fund Master Ltd. (+1) | Passiv (13G/A) | 1,30 % | 8.959.894 | +0,10 pp | |
| 15.05.2025 | VIKING GLOBAL INVESTORS LP (+3) | Passiv (13G/A) | 6,40 % | 46.013.752 | Neu | |
| 14.02.2025 | SB Investment Advisers (UK) Limited (+3) | Passiv (13G/A) | 8,50 % | 62.057.537 | -0,60 pp | |
| 14.02.2025 | QVT Financial LP | Passiv (13G/A) | 9,22 % | 65.793.779 | Neu | |
| 14.11.2024 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+3) | Passiv (13G/A) | 2,60 % | 18.959.447 | -1,00 pp | |
| 14.11.2024 | Viking Global Equities II LP | Passiv (13G/A) | 0,10 % | 530.019 | 0,00 pp | |
| 14.11.2024 | Viking Global Investors LP (+3) | Passiv (13G/A) | 7,30 % | 54.099.066 | -1,30 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 31.10.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 30.10.2025 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
| 30.10.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 17.06.2025 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-K | 8.260.000 $ | -299.771.000 $ | -0,54 $ | 5.708.687.000 $ | 4.527.370.000 $ |
| 2025-12-31 | 10-Q | 1.999.000 $ | -265.891.000 $ | -0,38 $ | 5.225.368.000 $ | 4.269.255.000 $ |
| 2025-09-30 | 10-Q | 1.571.000 $ | -113.519.000 $ | -0,17 $ | 5.062.598.000 $ | 4.362.331.000 $ |
| 2025-06-30 | 10-Q | 2.170.000 $ | -223.355.000 $ | -0,33 $ | 5.032.602.000 $ | 4.345.634.000 $ |
| 2025-03-31 | 10-K | 29.053.000 $ | -171.981.000 $ | -0,24 $ | 5.436.940.000 $ | 4.687.605.000 $ |
| 2024-12-31 | 10-K | 1.128.005.000 $ | – | – | – | – |
| 2024-12-31 | 10-Q | 9.018.000 $ | 169.381.000 $ | 0,23 $ | 5.792.345.000 $ | 5.189.472.000 $ |
| 2024-09-30 | 10-Q | 4.475.000 $ | -230.184.000 $ | -0,31 $ | 6.206.028.000 $ | 5.152.955.000 $ |
| 2024-06-30 | 10-Q | 7.990.000 $ | 95.297.000 $ | 0,12 $ | 6.496.448.000 $ | 5.435.309.000 $ |
| 2024-03-31 | 10-K | 32.713.000 $ | 4.348.926.000 $ | 5,23 $ | 7.222.482.000 $ | 5.968.581.000 $ |
| 2023-12-31 | 10-K | 991.107.000 $ | – | – | – | – |
| 2023-12-31 | 10-Q | 15.562.000 $ | 5.096.184.000 $ | 6,03 $ | 7.312.679.000 $ | 6.089.763.000 $ |
| 2023-09-30 | 10-Q | 3.648.000 $ | -304.327.000 $ | -0,40 $ | 2.065.543.000 $ | 948.534.000 $ |
| 2023-06-30 | 10-Q | 21.624.000 $ | -291.816.000 $ | -0,38 $ | 2.136.646.000 $ | 910.730.000 $ |
| 2023-03-31 | 10-K | 31.530.000 $ | -1.009.030.000 $ | -1,42 $ | 2.389.604.000 $ | 1.157.766.000 $ |
| 2022-12-31 | 10-K | 873.435.000 $ | – | – | – | – |
| 2022-12-31 | 10-Q | 17.052.000 $ | -352.014.000 $ | -0,49 $ | 2.202.960.000 $ | 955.520.000 $ |
| 2022-09-30 | 10-Q | 12.533.000 $ | -291.590.000 $ | -0,42 $ | 2.215.534.000 $ | 1.160.601.000 $ |
| 2022-06-30 | 10-Q | 4.319.000 $ | -331.809.000 $ | -0,48 $ | 2.600.398.000 $ | 1.384.111.000 $ |
| 2022-03-31 | 10-K | 55.286.000 $ | -845.262.000 $ | -1,26 $ | 2.585.129.000 $ | 1.656.944.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|
| Product | 75,1 Mio. | 28,0 Mio. | – | 60,1 % | +168,0% | |
| License Milestone And Other Revenue | 49,7 Mio. | 33,3 Mio. | 55,3 Mio. | 39,9 % | +49,5% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q3 2025 | 31.12.2025 | 06.02.2026 | 2,0 Mio. USD | -0,38 |
| Q2 2025 | 30.09.2025 | 10.11.2025 | 1,6 Mio. USD | -0,17 |
| Q1 2025 | 30.06.2025 | 11.08.2025 | 2,2 Mio. USD | -0,33 |
| Q3 2024 | 31.12.2024 | 10.02.2025 | 9,0 Mio. USD | 0,23 |
| Q2 2024 | 30.09.2024 | 12.11.2024 | 4,5 Mio. USD | -0,31 |
| Q1 2024 | 30.06.2024 | 09.08.2024 | 8,0 Mio. USD | 0,12 |
| Q3 2023 | 31.12.2023 | 13.02.2024 | 15,6 Mio. USD | 6,03 |
| Q2 2023 | 30.09.2023 | 13.11.2023 | 3,6 Mio. USD | -0,40 |
| Q1 2023 | 30.06.2023 | 14.08.2023 | 21,6 Mio. USD | -0,38 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 20.05.2026 | 10-K | 31.03.2026 | 50 Tage | SEC » |
| 06.02.2026 | 10-Q | 31.12.2025 | 37 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 29.05.2025 | 10-K | 31.03.2025 | 59 Tage | SEC » |
| 10.02.2025 | 10-Q | 31.12.2024 | 41 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 30.05.2024 | 10-K | 31.03.2024 | 60 Tage | SEC » |
| 13.02.2024 | 10-Q | 31.12.2023 | 44 Tage | SEC » |
| 13.11.2023 | 10-Q | 30.09.2023 | 44 Tage | SEC » |
| 14.08.2023 | 10-Q | 30.06.2023 | 45 Tage | SEC » |
| 28.06.2023 | 10-K | 31.03.2023 | 89 Tage | SEC » |
| 13.02.2023 | 10-Q | 31.12.2022 | 44 Tage | SEC » |
| 14.11.2022 | 10-Q | 30.09.2022 | 45 Tage | SEC » |
| 15.08.2022 | 10-Q | 30.06.2022 | 46 Tage | SEC » |
| 28.06.2022 | 10-K | 31.03.2022 | 89 Tage | SEC » |
| 14.02.2022 | 10-Q | 31.12.2021 | 45 Tage | SEC » |
| 15.11.2021 | 10-Q | 30.09.2021 | 46 Tage | SEC » |
| 21.09.2021 | 10-Q | 30.06.2021 | 83 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 06.10.2023 | Kapitalerhöhung | – | SEC » |
| 26.09.2023 | Kapitalerhöhung | – | SEC » |
| 06.02.2023 | Kapitalerhöhung | – | SEC » |
| 01.02.2023 | Kapitalerhöhung | – | SEC » |
| 09.11.2022 | Kapitalerhöhung | – | SEC » |
| 08.11.2022 | Kapitalerhöhung | – | SEC » |
| 03.10.2022 | Kapitalerhöhung | – | SEC » |
| 03.10.2022 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | Form | |
|---|---|---|---|
| 29.07.2025 | HV-Einladung | DEF 14A | SEC » |
| 29.07.2025 | HV-Einladung | DEFA14A | SEC » |
| 26.07.2024 | HV-Einladung | DEFA14A | SEC » |
| 26.07.2024 | HV-Einladung | DEF 14A | SEC » |
| 31.07.2023 | HV-Einladung | DEFA14A | SEC » |
| 31.07.2023 | HV-Einladung | DEF 14A | SEC » |
| 26.07.2022 | HV-Einladung | DEFA14A | SEC » |
| 26.07.2022 | HV-Einladung | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termine und Vergütung stehen im Dokument (SEC-Link).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 09.08.2021 | Fusion | S-4/A | Ziel: ROIVANT SCIENCES LTD | SEC » |
| 03.08.2021 | Fusion | S-4/A | Ziel: ROIVANT SCIENCES LTD | SEC » |
| 02.08.2021 | Fusion | 425 | Ziel: Immunovant, Inc. · $11,74 Cash | SEC » |
| 22.07.2021 | Fusion | S-4/A | Ziel: ROIVANT SCIENCES LTD | SEC » |
| 22.07.2021 | Fusion | 425 | Ziel: Montes Archimedes Acquisition Corp. | SEC » |
| 01.07.2021 | Fusion | S-4/A | Ziel: ROIVANT SCIENCES LTD | SEC » |
| 01.07.2021 | Fusion | 425 | Ziel: Montes Archimedes Acquisition Corp. | SEC » |
| 25.06.2021 | Fusion | 425 | – | SEC » |
| 21.06.2021 | Fusion | 425 | $10,00 (Struktur unklar) | SEC » |
| 09.06.2021 | Fusion | 425 | Ziel: Montes Archimedes Acquisition Corp. | SEC » |
| 09.06.2021 | Fusion | 425 | – | SEC » |
| 17.05.2021 | Fusion | 425 | Ziel: Montes Archimedes Acquisition Corp. | SEC » |
| 14.05.2021 | Fusion | S-4 | Ziel: ROIVANT SCIENCES LTD. | SEC » |
| 03.05.2021 | Fusion | 425 | Ziel: Roivant Sciences Ltd. | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
🔒 Die aufklappbare Detailanalyse (Red Flags, Risiko-Änderungen, Guidance-Zitate, voller Wortlaut) ist Teil des Kunden-Abos — freischalten.
| Datum | Form | Stimmung | Guidance | Risiko-Δ | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|---|
| 06.02.2026 | 10-Q | 0,15 | k. A. | 0,00 | 57 | Roivant verfügt über eine solide Liquiditätsbasis von 4,5 Mrd. USD und hat mit dem eingereichten NDA für Brepocitinib bei Dermatomyositis sowie mehreren erwarteten Phase-3-Datenpunkten in 2026 einen klar definierten Katalysatorkalender. Die Nettover… | 🔒 |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 20.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers… |
| 21.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.09.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 20.05.2026 | Quartalszahlen | 0,00 | 55 | Roivant Sciences Ltd. veröffentlichte am 20. Mai 2026 die Finanzergebnisse für das vierte Quartal und das Geschäftsjahr zum 31. März 2026. | SEC |
| 02.04.2026 | Sonstiges | 0,60 | 70 | Roivant Sciences gab am 2. April 2026 bekannt: Liquiditätsposition von 4,3 Mrd. USD, Aktienrückkauf von 3,96 Millionen Shares sowie neue Pha… 🔒 | SEC |
| 23.03.2026 | Wesentliche Vereinbarung | -0,10 | 55 | Roivant Sciences gibt den Abschluss einer wesentlichen Vereinbarung bekannt. Ein Settlement Agreement wird angekündigt, weitere Details befi… 🔒 | SEC |
| 03.03.2026 | Behördliche Maßnahme | 0,75 | 80 | FDA akzeptiert NDA für brepocitinib zur Behandlung von Dermatomyositis und gewährt Priority Review. Ein wichtiger Meilenstein für die Tochte… 🔒 | SEC |
| 03.03.2026 | Wesentliche Vereinbarung | 0,20 | 55 | Genevant/Arbutus einigten sich mit Moderna auf Settlement-Agreement. Roivant autorisierte Erhöhung des Aktienrückkauf-Programms auf $1,0 Mrd… 🔒 | SEC |
| 06.02.2026 | Quartalszahlen | 0,00 | 60 | Roivant Sciences veröffentlichte Geschäftsergebnisse für das vierte Quartal 2025 (zum 31. Dezember 2025). Weitere Details aus der Pressemitt… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 575 | 34,73 | 19.970 |
| 2026-06-29 | 448.710 | 34,07 | 15.287.550 |
| 2026-06-22 | 2.227 | 31,43 | 69.995 |
| 2026-06-15 | 12.109 | 30,04 | 363.754 |
| 2026-06-08 | 30.276 | 28,58 | 865.288 |
| 2026-06-01 | 38.910 | 29,99 | 1.166.911 |
| 2026-05-28 | 56.175 | 29,58 | 1.661.657 |
| 2026-05-26 | 2.206 | 29,96 | 66.092 |
| 2026-05-18 | 150 | 29,29 | 4.394 |
| 2026-05-13 | 379 | 29,39 | 11.139 |
| 2026-04-27 | 9 | 27,41 | 247 |
| 2026-04-17 | 612.895 | 29,19 | 17.890.405 |
| 2026-04-06 | 668 | 28,33 | 18.924 |
| 2026-03-31 | 122 | 26,41 | 3.222 |
| 2026-03-26 | 266 | 27,36 | 7.278 |
| 2026-03-25 | 49 | 26,87 | 1.317 |
| 2026-03-23 | 28 | 27,70 | 776 |
| 2026-03-03 | 2.411 | 28,10 | 67.749 |
| 2026-02-23 | 1.055.638 | 27,15 | 28.660.572 |
| 2026-02-20 | 1.399.610 | 27,52 | 38.517.267 |
| 2026-02-19 | 24 | 27,48 | 660 |
| 2026-02-18 | 6 | 27,09 | 163 |
| 2026-01-23 | 2.152 | 22,97 | 49.431 |